Replies to post #15780 on Momenta Pharmaceuticals, Inc. (MNTA)

[DewDiligence]

Any reason why NVS would prefer doing a 10b5-1 sale vs. a secondary offering?

A secondary offering by NVS would likely incur a small discount to the market price in addition to the underwriter's fee.